Bringing the fundamentals into focus…
Back to Recursion Pharmaceuticals, Inc.
How Recursion Pharmaceuticals, Inc. stacks up
RXRX · against 372 other Healthcare companies of similar size
Growth
17/ 100
Near the bottom of its peers.
Ranked #318 of 373 · scores higher than 14% of peers
Bars: peers in each 10-point band of the growth score33 peers with a growth score of 10–19, including RXRX · Click a bar to see the companies
Why growth scores 17?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and 3-year revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 88% of peers. Revenue growth: -15.1% vs peer median 6.1%
- slower revenue growth over three years: weaker than 61% of peers. 3-year revenue growth: 3.1% vs peer median 5.8%
- Earnings per share growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = RXRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RXRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 374 reported | -15.1% | 6.6% | 11% | 33% | |
| Earnings per share growthHigher is better · 209 reported | Not reported | 8.6% | — | — | 33% |
| 3-year revenue growthHigher is better · 365 reported | 3.1% | 7.8% | 36% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around RXRX| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 2 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 27.6B SEK (≈$2.8B) | 99 | 76 | |
| 2 | 2.1B USD | 99 | 96 | |
| 318 | 12.2B CNY (≈$1.7B) | 17 | 39 | |
| 318 | 7.1B CNY (≈$989M) | 17 | 38 | |
| 318 | 26.9B CNY (≈$3.8B) | 17 | 65 | |
| 318 | 12.8B CNY (≈$1.8B) | 17 | 36 | |
| 318 | 2.0B USD | 17 | 24 | |
| 323 | 21.6B CNY (≈$3.0B) | 16 | 41 | |
| 323 | 15.6B DKK (≈$2.3B) | 16 | 33 | |
| 325 | 23.8B CNY (≈$3.3B) | 15 | 54 | |
| 325 | 9.0B CNY (≈$1.3B) | 15 | 45 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score